Non-Hodgkin’s lymphoma novel pipeline is diverse and dominated by combination therapies

GlobalData Healthcare 4th September 2019 (Last Updated September 4th, 2019 16:50)

Combination therapies are the norm in non-Hodgkin’s lymphoma treatment, and the pipeline reflects that.

Non-Hodgkin’s lymphoma novel pipeline is diverse and dominated by combination therapies

The late-stage pipeline for non-Hodgkin’s lymphoma (NHL) contains a diverse range of mechanisms of action. 

Non-Hodgkin’s lymphoma treatment

The figure below displays ongoing trials for agents seeking a first approval in NHL. Of the seven therapies, two are targeting CD19 (Celgene’s lisocabtagene maraleucel and MorphoSys’ tafasitamab) while the remaining five each work against different targets. 

Combination therapies are the norm in NHL treatment, and the pipeline reflects that as lisocabtagene maraleucel and Amgen’s Blincyto are the only therapies being investigated as monotherapies, while the remainder is being investigated in combination with other therapies. 

Roche’s Polivy (polatuzumab vedotin-piiq) was recently approved by the US Food and Drug Administration (FDA), in June 2019, in combination with bendamustine and rituximab. GlobalData believes TG Therapeutics’ U2 regimen (ublituximab + umbralisib) will be the next therapy to achieve an FDA approval, in 2020.


 Source: GlobalData © GlobalData

CMR = complete metabolic response; DLT =dose-limiting toxicities ; EFS = event-free survival; ORR = overall response rate; OS = overall survival; PCD = primary completion date; PFS = progression-free survival; TLS = tumor lysis syndrome